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Abstract
The COVID-19 pandemic has posed challenges to the conduct of clinical trials. Strategies for overcoming common
challenges to non-COVID-19 trial continuation have been reported, but this literature is limited to pharmacological
intervention trials from high-income settings. The purpose of this paper is to expand the literature to include a low-
and middle-income country perspective. We describe the challenges posed by COVID-19 for a randomised
feasibility trial of a psychological intervention for adolescents in Cape Town, South Africa, and lessons learned when
implementing strategies to facilitate trial continuation in this context. We used a Plan-Do-Study-Act cycle method
to explore whether our adaptations were having the desired effect on trial accrual and retention. We found that
stakeholder engagement, trial coordination and team communication need to be intensified while testing these
procedural changes. We learned that strategies found to be effective in high-income countries required significant
adaptation to our resource-constrained setting. The detailed documentation of extraneous influences, procedural
changes and trial process information was essential to guiding decisions about which adaptations to retain. This
information will be used to examine the potential impact of these changes on study outcomes. We hope that
these reflections will be helpful to other trialists from low- and middle-income countries grappling with how to
minimise the impact of public health emergencies on their research.
Trial registration: The trial is registered with the Pan African Clinical Trials Registry (PACTR20200352214510).
Registered 28 February 2020. https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=9795.
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Background
Despite the promise of a vaccine, the COVID-19
pandemic continues to pose a threat to public health
[1]. In response to this global emergency, countries
have implemented various measures to contain the
spread of the disease and preserve health system
capacity by promoting social distancing and
restricting freedom of movement [2].
While necessary, these restrictions have had a pro-
found effect on non-COVID-19 clinical research.
Around the world, non-COVID-19 clinical trials have
been suspended or halted due to COVID-19 regulations,
sponsor or funder directives and operational challenges
[3–5]. Non-COVID-19 trials permitted to continue or
resume and required substantial adjustments to recruit-
ment, intervention, data collection and trial management
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protocols in response to the social distancing and quar-
antine challenges posed by COVID-19 [6, 7]. Recent sys-
tematic reviews and studies have reported that these
mitigation efforts have resulted in enrolment delays and
operational gaps that have negatively impacted on trial
timelines and outcomes [8, 9].
Various regulatory authorities have issued guidance for
trial conduct during the pandemic that includes recom-
mendations for adaptations to ensure participant safety
[10–13]. This guidance recommends virtual recruitment
and informed consent processes; the off-site administra-
tion of investigational products and procedures for vir-
tual data collection, remote study and safety monitoring,
remote data management; and the implications of these
adaptations for statistical analysis [10–14]. While some
of the guidance (e.g. [12]) details procedures for obtain-
ing informed consent virtually, the off-site provision of
investigational products and remote data management,
for the most part available guidance, offers few specifics
on how to adapt trial procedures to facilitate continu-
ation while minimising risks to trial integrity [14, 15].
Additionally, this guidance is largely focused on trials of
pharmacological interventions and does not address is-
sues around the remote delivery and fidelity monitoring
of non-pharmacological interventions.
To help operationalise this guidance, trialists are shar-
ing their strategies for mitigating against COVID-19
challenges to trial conduct. These challenges include re-
stricted access to health services, difficulty in recruiting
participants due to stay-at-home orders, concern that
trial procedures increase the risk of COVID-19 exposure
for participants and staff, higher attrition rates due to
difficulties in contacting participants and logistical chal-
lenges related to access to personal protective equipment
(PPE) [6, 7, 14–18]. While helpful, the literature re-
mains largely limited to trials conducted in high-
income countries (HICs). This is not surprising given
the underrepresentation of low- and middle-income
countries (LMICs) in trials methodology research
[19]. However, the growing investment in global
health trials [20] makes this an important gap to ad-
dress. Although many of the challenges described by
trialists in HICs are relevant, they are likely to be ex-
acerbated in trials conducted in LMICs due to pre-
existing logistical, resourcing and implementation is-
sues that make it difficult to conduct trials in these
settings [21–23]. Compared to HICs, trialists in
LMICs have substantially less access to health facil-
ities and other infrastructure required to conduct tri-
als, trained human resources and methodological
expertise, and financial resources to support clinical
trials [21, 22]. Additionally, COVID-19 restrictions
may amplify the context-specific challenges that affect
participant enrolment and retention in trials within
LMICs [22]. These include limited patient education
and support for trial participation; widespread socio-
economic adversity that limits access to technology,
transport and time to participate in trials; and greater
participant mobility (due to unstable housing and mi-
grant labour). As a result of these contextual, sys-
temic and population differences between HICs and
LMICs, strategies for mitigating COVID-19 obstacles
to trial conduct in HICs (such as online recruitment
and data collection) may be less feasible to use in
LMICs.
The purpose of this paper is to expand the discussion
on trial continuation during COVID-19 to include a
LMIC perspective. We describe the challenges posed by
COVID-19 for an ongoing randomised feasibility trial of
a psychological intervention for adolescents in Cape
Town, South Africa, and the strategies employed to fa-
cilitate trial continuation. We hope that these reflections
will be helpful to other trialists from LMICs grappling
with how to minimise the impact of public health emer-
gencies on their research.
Trial description
Recruitment for a randomised feasibility trial of an inter-
vention for reducing risk for depression and heavy alco-
hol use among South African adolescents (aged 15–18)
began on 04 November 2019. The original protocol is
described in [24] (trial registration: PACT
R20200352214510). Prior to COVID-19, field staff re-
cruited adolescents from disadvantaged neighbourhoods
using community-based outreach techniques. These in-
volved approaching young people in places that adoles-
cents frequent to describe the study and conduct
eligibility screening after obtaining their verbal consent.
The staff met with the parents of eligible adolescents
younger than 18 years old to describe the study and ob-
tain written informed consent for their child’s participa-
tion. After obtaining parental consent, the adolescent
was invited to a study enrolment visit. At this first ap-
pointment, their written informed assent for study par-
ticipation was obtained, an interviewer-administered
baseline assessment conducted and the first counselling
session was delivered before randomly assigning partici-
pants to the ASPIRE intervention (three additional coun-
selling sessions and referral to other services) or a
comparison condition (referral to other services). Coun-
selling was supported via a handbook summarising the
content of each session and containing worksheets for
practising the problem-solving method. All participants
were to be physically tracked in their communities to fa-
cilitate scheduling for the 6-week and 3-month post-
randomisation assessments where the baseline question-
naire was re-administered. All activities occurred at a
dedicated clinical research site.
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The COVID-19 trajectory in South Africa
On 27 March 2020, South Africa entered a strict na-
tional “level 5” lockdown that involved strict restrictions
to limit the spread of the virus (see Fig. 1), including the
prohibition of the sale and distribution of alcohol [25].
This led to all patient-interfacing non-COVID-19 re-
search being paused. By this time, the ASPIRE trial had
enrolled 67 participants of a planned 100. When re-
search was paused, only 15 of the 67 had completed the
full protocol. Although we were permitted to use remote
procedures to complete the study activities for partici-
pants enrolled in the trial, all new recruitment was sus-
pended. These restrictions were gradually lifted as the
country moved through the first wave of infections, with
some ethics committees permitting non-COVID-19 tri-
als to resume recruitment under strict conditions during
level 3 lockdown [26].
Sponsor and ethics committee stipulations for full
trial resumption
Prior to requesting resumption of recruitment, the prin-
cipal investigators (PIs) engaged with the sponsor (South
African Medical Research Council [SAMRC]) and the
two South African ethics committees that approved the
original trial (SAMRC, University of Cape Town (UCT))
to understand their requirements and conditions. The
trial sponsor and the SAMRC human research ethics
committee were willing to permit full trial resumption,
provided that field staff were trained in and imple-
mented COVID-19 safety protocols, all staff and partici-
pants completed daily COVID-19 screening and were
provided with PPE, and activities occurred in spaces that
allowed for good ventilation and social distancing.
However, the team was encouraged to limit face-to-face
participant contact. UCT’s Faculty of Health Sciences’
Human Research Ethics Committee had stricter require-
ments, only permitting remote contact between UCT-
employed field staff and participants. To ensure parity
and risk mitigation for all staff, the PIs substantially
adapted the trial protocols to minimise in-person
contact.
Adaptations to trial procedures in response to
COVID-19
On 4 June 2020, the ASPIRE trial was granted ethical
approval to resume recruitment with adapted protocols
(described below). Although some of these adaptations
posed potential challenges to the feasibility outcomes
and quality of the trial, they also presented opportunities
to test alternative ways of conducting mental health
intervention trials in resource-constrained settings.
Methods used to guide decisions about trial adaptations
We used the Plan-Do-Study-Act (PDSA) method [27] to
guide decision-making about the required protocol
changes. This approach was selected as it is pragmatic,
facilitates rapid assessment of small changes to current
procedures and uses feedback from the assessment to
improve the fit of the solution for the context [27, 28].
This method involves a four-stage cycle: the “plan” stage
involves identifying the desired change, the “do” stage
involves implementing the change, the success of this
change is evaluated in the “study” stage and further re-
finements to the original change are identified in the
“act” stage which informs the next cycle of practice im-
provement [28, 29].
Fig. 1 Timeline of the ASPIRE trial and COVID-19 pandemic in South Africa
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First, the investigators mapped out the potential obsta-
cles to trial recruitment, data collection and intervention
delivery and discussed possible strategies for addressing
these barriers during video calls with the funder repre-
sentative, sponsor, the institutional ethics committees
and the trial steering committee. Feedback from these
meetings guided the construction of a menu of possible
protocol change options. We amended our protocol and
sought ethics approval for the proposed strategies for fa-
cilitating trial continuation. We submitted a single re-
quest for a protocol amendment that described each of
the strategies and how we would implement these. Fol-
lowing approval, we incrementally implemented the pro-
posed changes to recruitment, data collection and
intervention delivery procedures. During weekly video
calls with the trial and counselling coordinators, the in-
vestigators used trial process data (accrual rate, attrition,
intervention sessions completed) to review and refine
the recruitment, data collection and intervention proto-
cols. The recruiters and data collectors met weekly with
the trial coordinator to provide feedback on how well
the changes had worked and ways in which these could
be refined. The counsellors provided similar feedback to
the counselling coordinator during their weekly meet-
ings. The coordinators shared the minutes of these
meetings and verbal feedback with the investigator team.
This was also used to inform further refinements to trial
procedures as needed.
Changes to recruitment and consent procedures
In response to COVID-19 concerns, we paused commu-
nity screening and recruitment, switching to a fully re-
mote process where adolescents could self-refer for
eligibility screening via telephone. To facilitate accrual,
we marketed the study by distributing study flyers and
posters at places accessible to young people during the
pandemic, on social media and to organisations provid-
ing COVID-19 relief services. Marketing materials con-
tained a telephone number that adolescents could
contact for further information. We also adapted paren-
tal consent and adolescent assent/consent procedures so
that consent/assent could be obtained via telephone,
with verbal consent being audio-recorded for audit pur-
poses. After participants were enrolled in the study, the
field team delivered hard copies of participant informa-
tion leaflets and consent/assent forms to the participant
and collected signed copies of these forms.
Although necessary, these changes affected the trial’s
accrual rate, with more than a 50% reduction in monthly
screening totals observed after switching to telephone
screening. This is not surprising as active case finding
through outreach is considered more effective than self-
referral for recruiting adolescents into psychological in-
terventions [30, 31]. With these changes, we observed an
increase in potential participants lost between screening
and informed consent/assent procedures. The propor-
tion of eligible adolescents whom we were unable to lo-
cate for informed consent/assent increased from 8.7 to
15.6% (p < 0.001) and the proportion of parents from
whom we were unable to obtain parental consent for
their child’s participation increased from 8.7 to 17.9% (p
< 0.001).
The switch to remote recruitment likely affected re-
cruiters’ ability to build rapport and gain the trust of po-
tential participants and their parents. Prior to COVID-
19, we had purposefully employed recruiters known and
respected in the communities to address issues of com-
munity mistrust of unknown researchers, a well-
documented barrier to adolescent participation in clin-
ical research [31]. Their good reputation in the commu-
nity and “references” from other community members
often served as an entry point with adolescents and par-
ents, affording recruiters the opportunity to meet with
parents to discuss the study and allay any concerns re-
lated to their child’s participation. With the remote
screening and consent processes, parental consent was
more challenging to obtain with several being hesitant
or refusing to allow their child to participate in a study
with strangers.
To address this obstacle, we asked trusted community
leaders and organisations providing support services to
vulnerable children and families to vouch for our trust-
worthiness and refer adolescents who they think have
unmet psychosocial needs to ASPIRE for screening. The
personal recommendations of these individuals and or-
ganisations appear to have improved the willingness of
parents and adolescents to engage with the ASPIRE
team.
Changes to data collection procedures
In addition, we changed our protocols to facilitate
telephonic data collection. While expedient, there
were logistic and environmental barriers to using this
approach that may have affected data quality and par-
ticipant retention. Most ASPIRE participants had lim-
ited access to a telephone—they lived in overcrowded,
low-income households that shared a single phone.
These living circumstances were not conducive to
privacy, potentially impacting their willingness to dis-
close sensitive information via telephone. With tele-
phonic data collection, field staff missed out on
important non-verbal clues for when to probe partici-
pant responses or rephrase sensitive questions for en-
hanced accuracy. The use of video call platforms like
Zoom and Skype may have overcome this challenge,
but most adolescents in our study had limited access
to the hardware needed to support this technology.
Poor connectivity (with calls disconnecting or being
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of poor quality) and background noise were other is-
sues that impacted telephonic data collection. We ex-
plored whether providing airtime or data to
adolescents improved their participation in the trial
but soon abandoned this strategy when it became
clear that hardware access and privacy concerns were
the primary barriers to telephonic data collection.
To limit the impact of these challenges on data quality,
we trained staff to adopt a flexible approach to schedul-
ing telephonic assessments at a time when participants
had access to a telephone and sufficient privacy. Second,
to minimise the impact of participant fatigue and call in-
terruptions on data quality, we re-ordered the question-
naires to prioritise the collection of primary outcome
data before asking about secondary outcomes. Third, we
obtained ethical approval to audio-record assessments to
monitor data collection quality. We have used these re-
cordings to verify the data captured on paper case report
forms and as a tool for training data collectors in strat-
egies for enhancing data quality.
Despite these efforts, we suspect that switching to tele-
phonic data collection contributed to a higher than the
anticipated loss to follow-up at the 6-week and 3-month
endpoints (20.5% at 6-week follow-up and 21.4% of par-
ticipants scheduled for a 3-month assessment). Notably,
87.5% of the participants lost for the 6-week follow-up,
and 91.3% of participants lost at the final endpoint oc-
curred when we were unable to physically track partici-
pants to remind them of their appointments. Telephonic
assessments may have been a less engaging experience
for adolescents than face-to-face assessments at our re-
search site—a place designed to be a welcoming environ-
ment for young people.
Changes to intervention protocols
The intervention was also adapted for telephone deliv-
ery. The shift from face-to-face to tele-counselling af-
fected the therapeutic alliance between counsellors and
participants, particularly for newly enrolled participants
who seemed less likely to engage and complete the inter-
vention if the initial session was delivered via telephone.
Specifically, 95.0% of participants who received face-to-
face counselling in session one completed session 2
compared to 84.2% of participants who obtained session
1 via telephone. In addition, 56.1% of participants who
received face-to-face counselling in session 1 completed
all four counselling sessions compared to 42.1% of par-
ticipants whose initial exposure to the counselling inter-
vention occurred via telephone.
Counsellors reported greater difficulty in teaching be-
havioural skills via telephone without being able to
gauge participants’ comprehension of counselling con-
tent. The logistic and environmental barriers to tele-
phonic data collection, described earlier, also impacted
counselling. Call interruptions impacted the flow and
duration of sessions. The lack of privacy to openly dis-
cuss problems was a concern for several participants,
raising questions about their ability to fully engage in
tele-counselling. COVID-19 also affected the team’s abil-
ity to refer adolescents for additional counselling, which
was key to ensuring the safety of participants with un-
met psychological needs. COVID-19 restrictions also af-
fected the community and health services to which we
had previously referred adolescents. Already in scarce
supply [32], these services were either non-operational
or could only provide limited services via remote
platforms.
To address these challenges, we introduced alternative
strategies for establishing rapport, promoting counselling
engagement, and ensuring participant safety. To combat
participant fatigue and attention difficulties, we split the
enrolment appointment into one contact for the baseline
assessment and a subsequent contact for the first coun-
selling session. Counsellors noted that this improved
participants’ ability to remain engaged throughout the
session. However, it also introduced additional oppor-
tunities for attrition, with seven participants being lost
to follow-up before meeting their counsellor and com-
pleting any counselling sessions. Counsellors tried to
limit attrition and establish initial rapport by engaging
with participants through introductory pamphlets and
videos to introduce themselves, remind them of their
upcoming counselling appointment and educate them
on what to expect from counselling.
Other strategies for reducing participant fatigue and
improving attention included giving participant’s
breaks to stretch their legs, introducing physical
movement into the session to raise energy and limit-
ing tele-counselling to key concepts with participants
being referred to the handbook for additional content,
examples and practice activities. We also delivered
counselling support packages to the homes of partici-
pants randomised to the ASPIRE intervention. These
contained the counselling handbooks, earphones so
that the session content could be listened to without
being overheard by others and a list of additional re-
sources that a participant could access for further
support. Strategies to ensure participant safety in the
absence of referral agencies included additional com-
munity case management for participants identified as
being at high risk for adverse mental health out-
comes. Case management involved re-screening par-
ticipants for CMD symptoms to assess safety risk,
crisis support (if required), provision of further refer-
rals to tele-counselling services and ongoing
monitoring.
With environmental constraints continuing to impact
counselling engagement for some participants, we
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adopted a hybrid approach to intervention delivery from
November 2020 after the further easing of lockdown re-
strictions. Most participants still received tele-
counselling, unless they expressed a preference for face-
to-face counselling or counsellors perceived an elevated
risk of attrition. Face-to-face counselling necessitated
adjusting trial operational procedures to further mitigate
COVID-19 risk for staff and participants.
Changes to trial management and operational procedures
In addition to augmenting operational procedures to in-
clude COVID-19 safety protocols, we also adjusted team
organisation, communication and staff management pro-
cedures to allow for flexibility and agility in responding
to a rapidly changing landscape. To ensure study con-
tinuity in the event of a staff member becoming ill or ex-
posed to COVID-19, we created two separate field teams
to minimise the risk of the whole team being exposed to
COVID-19. However, COVID-19 infections within these
teams still impacted the pace of study activities. We also
adjusted work schedules to allow for greater flexibility.
This flexibility included working after hours and on
weekends to accommodate the changing needs of partic-
ipants and staff whose caregiving responsibilities in-
creased because of school closures.
These changes increased the need for greater fre-
quency of field team communication and intensity of
team coordination. In response, we introduced daily
team meetings using online platforms, a WhatsApp
communication group for counsellors and recruiters to
coordinate the scheduling of assessment and counselling
appointments, and daily feedback from the counsellors
to the counsellor supervisor to facilitate coordination of
counselling activities. Training and supervision for the
data collectors also moved online. Counselling supervi-
sion took place via telephone, with the supervisor avail-
able via online platforms for real-time support to
address any potential challenges as staff adjusted to
these new protocols. This daily communication provided
team members with opportunities to share the frustra-
tions of conducting a trial in the context of a pandemic;
rapidly review and problem solve challenges to recruit-
ment, data collection and counselling; and support team
members struggling with pandemic-associated distress.
Responding to the potential impact of COVID-19
and protocol changes on trial outcomes
Despite our efforts, the stressors and strains associated
with the pandemic may have diluted the effects of the
ASPIRE intervention and standard of care. The illness
and death of family members, social isolation associated
with lockdown regulations, school closures and loss of
education time, and worsening food insecurity (due to
growing unemployment and halting of school feeding
schemes) have almost certainly impacted the psycho-
logical well-being of South African adolescents [33].
ASPIRE participants in the control arm received a single
intervention session and referral to standard care,
namely non-government organisations and public health
facilities serving adolescents. With major disruptions to
standard care being reported [34], difficulties in acces-
sing standard care may inflate the effects of the ASPIRE
intervention. As we did not collect detailed information
on the provision of standard care, we cannot assess the
impact of COVID-19 on access to standard care for
ASPIRE participants. We plan to remedy this oversight
in a future effectiveness trial.
For the ASPIRE trial, the country’s intermittent bans
on the sale and distribution of alcohol will add another
layer of complexity to the interpretation of trial out-
comes related to alcohol use. These bans spanned from
27 March to 1 June 2020, 13 July to 16 August 2020,
and 28 December 2020 to 1 February 2021. As adoles-
cent alcohol use is greatly influenced by community
availability [35, 36], we anticipate that these bans will
impact the frequency and quantity of alcohol consumed
by participants.
To account for the impact of these contextual changes
on our feasibility outcomes, we are documenting govern-
ment restrictions on movement, school access, alcohol,
and tobacco use, and any other major disruptive events
so these can be factored into the analyses and consid-
ered when interpreting results. Second, we are collecting
additional information on participants’ exposure to
COVID-19 and the impact of COVID-19 on access to al-
cohol, school attendance and learning, and mental health
at each study assessment. These data will add to the
emerging literature on the psychological effects of
COVID-19 and lockdown restrictions on adolescents liv-
ing in LMICs. Third, we are documenting the protocols
under which participants are enrolled, data collected and
interventions provided so that we can explore differ-
ences in feasibility (accrual, intervention and study re-
tention rates) and clinical outcomes among participants
enrolled under different protocols. While unplanned,
these protocol changes will allow us to explore the feasi-
bility of various recruitment, data collection and inter-
vention delivery approaches that may be useful as we
plan for a larger trial. To ensure we have enough partici-
pants enrolled under each protocol to allow for mean-
ingful comparisons, we increased our recruitment target
and extended our enrolment period.
Impact of COVID-19 protocol changes on timeline
and budget
Research pauses and procedural changes due to COVID-
19 regulations resulted in trial recruitment taking 8
months longer than planned. This has had a knock-on
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effect, delaying completion of the intervention, 6-week
and 3-month post-enrolment assessments, and qualita-
tive process evaluation interviews. The trial is ongoing,
with some 3-month assessments and process evaluation
interviews still pending. We anticipate that the combin-
ation of these study pauses and protocol changes will ex-
tend the trial timeline by 10 months. These delays also
increased the cost of conducting the trial. The original
budget for field personnel (project coordinator, asses-
sors, counsellors) increased by 48%. Although some of
the protocol changes did result in cost savings (for ex-
ample, the budget for travel decreased by 60%), there
were other unplanned costs including computer hard-
ware for staff, data costs and costs of PPE. Our institu-
tions have supported us in managing these budgetary
challenges by allowing investigators to charge less to the
project and provide in-kind support. Since 2018, when
the grant was awarded, the local currency (South African
Rand) has depreciated significantly against the British
pound. We have used these foreign exchange savings to
counter the budgetary challenges, but the trial did not
have sufficient funding to introduce other COVID-19
mitigation strategies such as rapid diagnostic testing
(RDT) when these were approved for use by the South
African Health Products Regulatory Authority on 25 Au-
gust 2020.
Discussion
Prior research has reported various strategies to ensure
the continuation and/or resumption of non-COVID-19
trials during the pandemic [6, 7]. As these reports have
been restricted in scope to pharmacological interven-
tions and HIC perspectives, they may have limited utility
to trialists testing psychological interventions in low-
resource settings where trial conduct is substantially
more challenging [21, 22]. This paper begins to address
this gap by describing strategies employed to enable the
continuation of a non-pharmacological intervention trial
for adolescent populations in a LMIC during this global
emergency.
Through adapting the ASPIRE trial recruitment, inter-
vention and data collection protocols for COVID-19 re-
sponsiveness, we learned three key lessons that may be
helpful to other trialists from LMICs. First, switching to
remote data collection and intervention delivery is not
simple to implement in low-resource settings—even
though much of the COVID-19 trial guidance and litera-
ture from HICs recommends this as a mitigation strat-
egy [10–12, 15]. Although there are concerns that
remote trial processes may lead to digital exclusion of
vulnerable individuals in HICs (such as individuals of
low SES who face financial and privacy barriers to en-
gagement in remote research) [37, 38], the likelihood of
digital exclusion is greater in LMICs. Most of the offline
population live in African LMICs [39], where much of
the populace lives below the breadline and where electri-
city, internet and mobile telephone access is often un-
stable [40]. From our experience, access to mobile
devices, connectivity issues (quality and interruptions)
and lack of privacy within households are likely to pose
significant challenges to data quality and engagement in
non-pharmacological interventions in LMICs. Our team
has learned the importance of acknowledging limitations
to remote processes and considering tactics to minimise
the impact of these limitations on trial accrual, data
quality and attrition when planning for remote trial pro-
cesses. The saliency of these difficulties for adolescents
in the ASPIRE trial also cautions against solely relying
on tele-health for mental health care provision in future
trials with adolescents in LMICs [41, 42]. To avoid
digital exclusion and the exacerbation of inequalities in
access to services, some adolescents will continue to re-
quire face-to-face contact. As COVID-19 rapid diagnos-
tic tests become more accessible, future trials could
consider the use of these tests to further mitigate the
risks of COVID-19 during face-to-face recruitment and
data collection procedures.
Second, we learned the value of collecting detailed infor-
mation on major disruptive events and contextual changes
that impact study participants and their families. We ex-
tracted information on the nature, onset and duration of
these disruptions from print documents (such as the
media and COVID-19 policy documents). We also col-
lected this information directly from study participants to
enhance understanding of the personal impact of these
changes. With this information, we plan to identify par-
ticipant sub-groups providing outcomes during these dis-
ruptions and explore the potential impact of these
changes on study outcomes. Beyond the COVID-19 pan-
demic, we argue that collecting detailed information on
social and environmental disruptions is critical for suc-
cessful trial management and should be routinely col-
lected as part of trial monitoring, particularly in contexts
where disruptions due to political conflict, community
violence and other humanitarian crises commonly occur.
Third, continuous monitoring of trial process indica-
tors is necessary for assessing whether adjustments to
recruitment, data collection and intervention protocols
had the desired effect. With COVID-19 being unprece-
dented, we lacked evidence to guide initial protocol
adaptation decisions and were forced to learn by doing.
Learning was facilitated through PDSA cycles. Although
PDSA is a frequently used process for quality improve-
ment in health services [27–29], it has rarely used to
identify and test improvements to trial procedures.
Several lessons were learned while using PDSA to test
small changes to trial procedures that may be useful to
other trialists seeking to improve their procedures. Early
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and regular engagement with the sponsor, ethics com-
mittees and trial steering committee can assist in map-
ping out a menu of possible change options. We sought
approval for each of these changes in a single protocol
amendment, avoiding the time delays associated with
multiple requests for protocol amendments. Second,
implementing a series of small changes augmented the
need for communication and coordination within the
field team and between the field team and investigators.
Field team feedback on whether changes were having
the desired effect or unanticipated challenges was inte-
gral to reviewing and refining procedural adaptations.
Third, the success of a PDSA cycle is contingent on col-
lecting detailed information from trial process indicators,
so the feasibility, impact on outcomes and cost of alter-
native recruitment, data collection and intervention de-
livery methods can be explored. For the ASPIRE trial,
these included the (1) nature, dates and duration of all
procedural changes; (2) the participants affected by these
changed protocols; and (3) staff hours spent on each
study activity.
To conclude, COVID-19 has forced us (like many tri-
alists) to change our original study protocols to allow for
trial continuation during this public health emergency.
Unlike an effectiveness trial where numerous changes to
the trial protocol would raise questions about trial integ-
rity, this trial’s focus on feasibility rather than clinical
outcomes allowed us to adapt and test a variety of study
procedures [43]. These changes have presented us with
an opportunity to explore the feasibility of alternative re-
cruitment, data collection and intervention delivery
methods and to gather data on how particular subgroups
of participants respond to each of these methods. As
part of the trial’s process evaluation, we are conducting
post-study interviews with trial participants in which we
will explore their experiences of the procedural changes
and preferences. These data, together with the trial
process data, will be used to improve the feasibility and
acceptability of trial procedures employed in a definitive
effectiveness trial. Further, our application of a quality
improvement approach to assessing whether these alter-
natives improved performance on feasibility indicators
may be useful to other trialists grappling with these deci-
sions. Through responding to these threats to study
completion, we have learned that stakeholder engage-
ment, trial coordination with regular and effective team
communication, and detailed documentation of extrane-
ous influences, procedural changes and trial process in-
formation intensify in importance and are critical to
evidence-based and agile responses to crises.
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